Tumour markers in chronic heart failure. Review of the literature and clinical implications

Journal of Cardiovascular Medicine

Volumn 7, Issue 8, 2006, Pages 573-579

  Faggiano, Pompilio ^a,c   D'Aloia, Antonio ^a   Antonini Canterin, Francesco ^b   Vizzardi, Enrico ^a   Nicolosi, Gian Luigi ^b   Cas, Livio Dei ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

CA 125 CA; Carbohydrate antigen; Congestive heart failure; Tumour markers

Indexed keywords

CARBOHYDRATE ANTIGEN; CARBOHYDRATE ANTIGEN 125; CATECHOLAMINE; CYTOKINE; NATRIURETIC FACTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIGEN STRUCTURE; BLOOD ANALYSIS; DISEASE SEVERITY; HEART FAILURE; HUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

CA-125 ANTIGEN; CHRONIC DISEASE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33748475710     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000237903.95882.06     Document Type: Review

References (32)

1. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med 1991; 115:623-638.
2. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002; 48:1151-1159.
3. Bast RC Jr, Klug TL, John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883-887.
4. O'Brien TJ, Tanimoto H, Konishi I, Gee M. More than 15 years of CA 125: what is known about the antigen, its structure and its function. Int J Biol Markers 1998; 13:188-195.
5. Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C. Elevation of CA 125 in patients with benign and malignant ascites. Cancer 1987; 59:213-217.
6. Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y, Uslu T, et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 2002; 85:108-113.
7. Miralles C, Orea M, Espana P, Provencio M, Sanchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003; 10:150-154.
8. Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA 125 and its relation to cardiac function. Am Heart J 1999; 137:1044-1049.
9. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003; 41:1805-1811.
10. Epiney M, Bertossa C, Weil A, Campana A, Bischof P. CA 125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000; 15:1261-1265.
11. Sjovall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 2002; 85:175-178.
12. Talbot RW, Jacobsen DJ, Nagorney DM, Malkasian GD, Ritts RE Jr. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet 1989; 168:407-412.
13. Sevinc A, Buyukberber S, Sari R, Turk HM, Ates M. Elevated serum CA-125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res 2000; 20:1201-1203.
14. Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 2000; 77:254-257.
15. Lindgren J, Kuusela P, Hellstrom PE, Pettersson T, Klockars M. The ovarian cancer associated antigen CA 125 in patients with pleural effusions. Eur J Cancer Clin Oncol 1988; 24:737-739.
16. Seo T, Ikeda Y, Onaka H, Hayashi T, Kawaguchi K, Kotake C, et al. Usefulness of serum CA 125 measurement for monitoring pericardial effusion. Jpn Circ J 1993; 57:489-494.
17. Sevinc A, Camci C, Turk HM, Buyukberber S. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 2003; 65:1-6.
18. Faggiano P, D'Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, et al. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 2005; 7:57-61.
19. Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, et al. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 2003; 24:172-175.
20. Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005; 7:199-203.
21. Varol E, Ozaydin M, Dogan A, Kosar F. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 2005; 7:840-843.
22. Popescu AC, Popescu BA, Antonini-Canterin F, Rivaben D, Rubin D, Cappelletti P, et al. Association between echocardiographic parameters of diastolic dysfunction and serum levels of carbohydrate antigen 125 [in Italian] [abstract]. Ital Heart J 2005; 6 (suppl 4):10S.
23. Duman C, Ercan E, Tengiz I, Bozdemir H, Ercan HE, Nalbantgil I. Elevated serum CA 125 levels in mitral stenotic patients with heart failure. Cardiology 2003; 100:7-10.
24. Antonini-Canterin F, Popescu AC, Popescu BA, Rubin D, Cappelletti P, Piazza R, et al. Measurement of serum levels of carbohydrate antigen 125 in patients with aortic valve stenosis [abstract]. Eur Heart J 2004; 25:592.
25. Zeimet AG, Offner FA, Marth C, Heim K, Feichtinger H, Daxenbichler G, et al. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 1997; 17:3129-3131.
26. Kubonishi I, Bandobashi K, Murata N, Daibata M, Ido E, Sonobe H, et al. High serum levels of CA125 and interleukin-6 in a patient with Ki-1 lymphoma. Br J Haematol 1997; 98:450-452.
27. Marth C, Zeimet AG, Widschwendter M, Daxenbichler G. Regulation of CA 125 expression in cultured human carcinoma cells. Int J Biol Markers 1998; 13:207-209.
28. Sharma R, Rauchhaus M, Ponikowski PP, Varney S, Poole-Wilson PA, Mann DL, et al. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2000; 36:523-528.
29. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997; 79:1128-1131.
30. Riese J, Schoolmann S, Denzel C, Herrmann O, Hohenberger W, Haupt W. Effect of abdominal infections on peritoneal and systemic production of interleukin 6 and monocyte chemoattractant protein-1. Shock 2002; 17:361-367.
31. Faggiano P, D'Aloia A, Bignotti T, Dei Cas L. One biologic marker (carbohydrate antigen-CA 125), two different diseases (ovarian cancer and congestive heart failure): practical implications of monitoring CA 125 serum levels. A case report. Ital Heart J 2003; 4:497-499.
32. D'Aloia A, Faggiano P, Brentana L, Boldini A, Procopio R, Racheli M, et al. A difficult diagnosis: right unilateral cardiogenic pulmonary edema. Usefulness of biochemical markers of heart failure for the correct diagnosis. Ital Heart J 2005; 6:771-774.